{'52WeekChange': 0.9749373,
 'SandP52WeekChange': None,
 'address1': '700 Technology Drive',
 'address2': 'Third Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.99,
 'askSize': 800,
 'averageDailyVolume10Day': 215851,
 'averageVolume': 420588,
 'averageVolume10days': 215851,
 'beta': None,
 'beta3Year': None,
 'bid': 7.26,
 'bidSize': 1000,
 'bookValue': 0.587,
 'category': None,
 'circulatingSupply': None,
 'city': 'Pittsburgh',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.81,
 'dayLow': 7.42,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.422,
 'enterpriseToRevenue': None,
 'enterpriseValue': 166689264,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 8.838285,
 'fiftyTwoWeekHigh': 11.78,
 'fiftyTwoWeekLow': 4.02,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16080505,
 'forwardEps': -1.53,
 'forwardPE': -4.8758173,
 'fromCurrency': None,
 'fullTimeEmployees': 11,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.21801001,
 'heldPercentInstitutions': 0.16915001,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1569801600,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/neubasetherapeutics.com',
 'longBusinessSummary': 'NeuBase Therapeutics, Inc., a pre-clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'of therapies to treat rare genetic diseases and '
                        "cancers caused by mutant genes. The company's "
                        'proprietary peptide-nucleic acid antisense '
                        'oligonucleotide (PATrOL) platform focuses on '
                        "addressing Huntington's disease (HD) and myotonic "
                        'dystrophy, as well as other genetic disorders. Its '
                        'lead programs include NT0100, a PATrOL-enabled '
                        'therapeutic program for systemic administration to '
                        'target the mutant expansion in the HD messenger '
                        'ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled '
                        'therapeutic program for systemic administration to '
                        'target the mutant expansion in the myotonic dystrophy '
                        'type 1 disease mRNA. NeuBase Therapeutics, Inc. is '
                        'headquartered in Pittsburgh, Pennsylvania.',
 'longName': 'NeuBase Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 172476688,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_596992951',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -32323768,
 'nextFiscalYearEnd': 1632960000,
 'open': 7.81,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.09,
 'phone': '646-450-1790',
 'previousClose': 7.88,
 'priceHint': 2,
 'priceToBook': 12.708688,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.81,
 'regularMarketDayLow': 7.42,
 'regularMarketOpen': 7.81,
 'regularMarketPreviousClose': 7.88,
 'regularMarketPrice': 7.81,
 'regularMarketVolume': 197845,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 23120200,
 'sharesPercentSharesOut': 0.043899998,
 'sharesShort': 1014802,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 539561,
 'shortName': 'NeuBase Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0495,
 'shortRatio': 1.93,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'NBSE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.259,
 'twoHundredDayAverage': 7.6011887,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'dd3cf6cf-f9cd-3b1e-9591-aeb04f3b643b',
 'volume': 197845,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.neubasetherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '15219'}